Compare Stocks: TRDA, KURA, ALMS, and ANL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$7.44 -8.3%	$20.35	$3.76 ▼ $31.35	$1.05B	-0.81	4.84 million shs	2.69 million shs
ANL Adlai Nortye	$15.75 -5.1%	$13.89	$0.88 ▼ $17.25	$1.07B	1.04	164,403 shs	218,130 shs
KURA Kura Oncology	$11.04 -5.9%	$11.22	$7.36 ▼ $13.90	$1.04B	0.44	1.79 million shs	2.77 million shs
TRDA Entrada Therapeutics	$6.50 -3.1%	$6.95	$5.08 ▼ $16.45	$261.27M	-0.25	299,053 shs	282,769 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	+2.66%	-3.45%	-66.45%	-67.36%	+95.42%
ANL Adlai Nortye	+6.62%	+10.67%	+21.17%	+51.05%	+882.25%
KURA Kura Oncology	+1.12%	+3.81%	-1.35%	+10.45%	+44.99%
TRDA Entrada Therapeutics	+1.05%	-2.47%	-11.36%	-11.01%	+27.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$7.44 -8.3%	$20.35	$3.76 ▼ $31.35	$1.05B	-0.81	4.84 million shs	2.69 million shs
ANL Adlai Nortye	$15.75 -5.1%	$13.89	$0.88 ▼ $17.25	$1.07B	1.04	164,403 shs	218,130 shs
KURA Kura Oncology	$11.04 -5.9%	$11.22	$7.36 ▼ $13.90	$1.04B	0.44	1.79 million shs	2.77 million shs
TRDA Entrada Therapeutics	$6.50 -3.1%	$6.95	$5.08 ▼ $16.45	$261.27M	-0.25	299,053 shs	282,769 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	+2.66%	-3.45%	-66.45%	-67.36%	+95.42%
ANL Adlai Nortye	+6.62%	+10.67%	+21.17%	+51.05%	+882.25%
KURA Kura Oncology	+1.12%	+3.81%	-1.35%	+10.45%	+44.99%
TRDA Entrada Therapeutics	+1.05%	-2.47%	-11.36%	-11.01%	+27.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMS Alumis	2.85	Moderate Buy	$33.27	347.21% Upside
ANL Adlai Nortye	2.71	Moderate Buy	$29.50	87.30% Upside
KURA Kura Oncology	2.75	Moderate Buy	$25.40	130.07% Upside
TRDA Entrada Therapeutics	2.50	Moderate Buy	$17.75	173.08% Upside

Current Analyst Ratings Breakdown

Latest TRDA, KURA, ALMS, and ANL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	ALMS Alumis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/10/2026	ANL Adlai Nortye	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$31.00
9/8/2026	ANL Adlai Nortye	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$49.00
9/8/2026	ANL Adlai Nortye	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/3/2026	ALMS Alumis	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
9/2/2026	ALMS Alumis	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$55.00 ➝ $37.00
9/2/2026	ALMS Alumis	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$39.00 ➝ $29.00
9/2/2026	ALMS Alumis	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $25.00
9/2/2026	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$25.00 ➝ $15.00
9/1/2026	ALMS Alumis	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$27.00

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMS Alumis	$24.05M	40.04	N/A	N/A	$2.88 per share	2.58
ANL Adlai Nortye	$5M	202.86	N/A	N/A	($0.21) per share	-75.00
KURA Kura Oncology	$67.48M	14.55	N/A	N/A	$2.00 per share	5.52
TRDA Entrada Therapeutics	$25.42M	9.96	N/A	N/A	$8.01 per share	0.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMS Alumis	-$243.32M	-$3.86	N/A	N/A	N/A	-5,933.46%	-93.15%	-74.50%	11/12/2026 (Estimated)
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)
TRDA Entrada Therapeutics	-$143.75M	-$3.96	N/A	N/A	N/A	-3,537.73%	-57.61%	-46.54%	11/5/2026 (Estimated)

Latest TRDA, KURA, ALMS, and ANL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ALMS Alumis	-$0.7670	-$1.11	-$0.3430	-$1.11	$3.65 million	$1.66 million
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/5/2026	Q2 2026	TRDA Entrada Therapeutics	-$0.9738	-$1.01	-$0.0363	-$1.01	$2.32 million	$0.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMS Alumis	N/A	6.74	6.74
ANL Adlai Nortye	0.04	9.55	0.65
KURA Kura Oncology	0.12	4.73	4.71
TRDA Entrada Therapeutics	N/A	10.89	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMS Alumis	N/A
ANL Adlai Nortye	35.21%
KURA Kura Oncology	N/A
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
ALMS Alumis	33.70%
ANL Adlai Nortye	N/A
KURA Kura Oncology	7.60%
TRDA Entrada Therapeutics	9.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMS Alumis	239	129.43 million	85.82 million	N/A
ANL Adlai Nortye	109	64.40 million	N/A	Not Optionable
KURA Kura Oncology	260	88.96 million	82.20 million	Optionable
TRDA Entrada Therapeutics	152	38.94 million	35.24 million	Optionable

TRDA, KURA, ALMS, and ANL Headlines

Recent News About These Companies

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Rating of "Moderate Buy" from Analysts

September 23 at 4:28 AM | marketbeat.com

Entrada Therapeutics, Inc.: Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

September 10, 2026 | finanznachrichten.de

Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

September 10, 2026 | globenewswire.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 28,837 Shares of Stock

September 10, 2026 | insidertrades.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $205,607.81 in Stock

September 9, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 38,500 Shares

September 9, 2026 | marketbeat.com

Bioventures 2018 L.P. Mpm Sells 192,500 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

September 9, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Definitive Healthcare Corp (DH) and Entrada Therapeutics Inc (TRDA)

September 5, 2026 | theglobeandmail.com

Entrada Therapeutics (NASDAQ:TRDA) Upgraded at Wall Street Zen

September 5, 2026 | marketbeat.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $180,691.89 in Stock

September 4, 2026 | insidertrades.com

BlackRock Inc. Invests $19.01 Million in Entrada Therapeutics, Inc. $TRDA

September 4, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $180,691.89 in Stock

September 3, 2026 | marketbeat.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $205,361.28 in Stock

September 3, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 32,263 Shares of Stock

September 3, 2026 | marketbeat.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2026 | globenewswire.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $26,168.33 in Stock

September 1, 2026 | insidertrades.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $26,168.33 in Stock

August 31, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 38,922 Shares

August 31, 2026 | marketbeat.com

Bioventures 2018 L.P. Mpm Sells 44,259 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

August 31, 2026 | marketbeat.com

300,575 Shares in Entrada Therapeutics, Inc. $TRDA Bought by Nantahala Capital Management LLC

August 29, 2026 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Rating of "Moderate Buy" by Brokerages

August 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, KURA, ALMS, and ANL Company Descriptions

Alumis NASDAQ:ALMS

$7.44 -0.67 (-8.26%)

Closing price 04:00 PM Eastern

Extended Trading

$7.52 +0.09 (+1.14%)

As of 07:30 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Adlai Nortye NASDAQ:ANL

$15.75 -0.85 (-5.12%)

Closing price 04:00 PM Eastern

Extended Trading

$15.65 -0.10 (-0.63%)

As of 07:30 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Kura Oncology NASDAQ:KURA

$11.04 -0.69 (-5.88%)

Closing price 04:00 PM Eastern

Extended Trading

$11.08 +0.04 (+0.32%)

As of 07:41 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Entrada Therapeutics NASDAQ:TRDA

$6.50 -0.21 (-3.13%)

Closing price 04:00 PM Eastern

Extended Trading

$6.50 0.00 (0.00%)

As of 07:30 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRDA, KURA, ALMS, and ANL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRDA, KURA, ALMS, and ANL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRDA, KURA, ALMS, and ANL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, KURA, ALMS, and ANL Company Descriptions

Alumis NASDAQ:ALMS

Adlai Nortye NASDAQ:ANL

Kura Oncology NASDAQ:KURA

Entrada Therapeutics NASDAQ:TRDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRDA, KURA, ALMS, and ANL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRDA, KURA, ALMS, and ANL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRDA, KURA, ALMS, and ANL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, KURA, ALMS, and ANL Company Descriptions

Alumis NASDAQ:ALMS

Adlai Nortye NASDAQ:ANL

Kura Oncology NASDAQ:KURA

Entrada Therapeutics NASDAQ:TRDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools